C R Bard Inc (BCR) Given Average Recommendation of “Hold” by Analysts

Shares of C R Bard Inc (NYSE:BCR) have received a consensus rating of “Hold” from the twelve research firms that are presently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating and one has given a buy rating to the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $319.17.

BCR has been the subject of several recent analyst reports. Zacks Investment Research raised shares of C R Bard from a “hold” rating to a “buy” rating and set a $372.00 target price for the company in a research note on Tuesday, December 26th. Barclays boosted their price objective on shares of C R Bard from $245.00 to $337.00 and gave the company an “equal weight” rating in a research note on Monday, November 6th. ValuEngine cut shares of C R Bard from a “buy” rating to a “hold” rating in a research note on Friday, December 1st. Cowen reissued a “hold” rating and set a $317.00 price objective on shares of C R Bard in a research note on Friday, November 3rd. Finally, Needham & Company LLC reissued a “hold” rating on shares of C R Bard in a research note on Thursday, October 26th.

C R Bard (NYSE BCR) remained flat at $$331.24 during mid-day trading on Tuesday. The company has a market capitalization of $24,140.00, a price-to-earnings ratio of 43.64, a PEG ratio of 2.53 and a beta of 0.52. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.72 and a quick ratio of 1.37. C R Bard has a one year low of $222.42 and a one year high of $337.73.

C R Bard (NYSE:BCR) last released its earnings results on Wednesday, October 25th. The medical instruments supplier reported $3.02 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $2.96 by $0.06. The firm had revenue of $989.80 million during the quarter, compared to analysts’ expectations of $990.64 million. C R Bard had a net margin of 9.51% and a return on equity of 19.39%. C R Bard’s revenue for the quarter was up 5.1% on a year-over-year basis. During the same period in the previous year, the company earned $2.64 EPS. sell-side analysts expect that C R Bard will post 11.89 EPS for the current year.

In other news, insider Christopher S. Holland sold 38,242 shares of the business’s stock in a transaction on Thursday, November 2nd. The shares were sold at an average price of $334.04, for a total transaction of $12,774,357.68. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director David M. Barrett sold 3,344 shares of the business’s stock in a transaction on Monday, October 30th. The shares were sold at an average price of $327.31, for a total transaction of $1,094,524.64. The disclosure for this sale can be found here. Insiders have sold a total of 114,602 shares of company stock valued at $38,193,867 over the last three months. Corporate insiders own 0.80% of the company’s stock.

Large investors have recently bought and sold shares of the stock. Monroe Bank & Trust MI lifted its holdings in shares of C R Bard by 65.6% during the 3rd quarter. Monroe Bank & Trust MI now owns 447 shares of the medical instruments supplier’s stock valued at $100,000 after acquiring an additional 177 shares in the last quarter. Valeo Financial Advisors LLC acquired a new position in shares of C R Bard during the 3rd quarter valued at $170,000. Patten Group Inc. lifted its holdings in shares of C R Bard by 66.0% during the 3rd quarter. Patten Group Inc. now owns 556 shares of the medical instruments supplier’s stock valued at $106,000 after acquiring an additional 221 shares in the last quarter. Choate Investment Advisors acquired a new position in shares of C R Bard during the 2nd quarter valued at $201,000. Finally, Glovista Investments LLC acquired a new position in shares of C R Bard during the 2nd quarter valued at $221,000. Institutional investors and hedge funds own 79.11% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This story was first reported by Community Financial News and is owned by of Community Financial News. If you are accessing this story on another domain, it was illegally stolen and republished in violation of United States & international trademark & copyright laws. The original version of this story can be accessed at https://www.com-unik.info/2018/01/21/c-r-bard-inc-bcr-given-average-recommendation-of-hold-by-analysts.html.

About C R Bard

C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.

Analyst Recommendations for C R Bard (NYSE:BCR)

Receive News & Ratings for C R Bard Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C R Bard and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit